Observational Study
Copyright ©The Author(s) 2024.
World J Radiol. Apr 28, 2024; 16(4): 82-93
Published online Apr 28, 2024. doi: 10.4329/wjr.v16.i4.82
Table 1 Spectrum of lesions in histopathology
Final diagnosis
Number of lesions
Percentage (%)
Ameloblastomas2035
Central giant cell granuloma1119
Odontogenic keratocyst610
Ossifying fibroma58
Salivary gland tumors24
Malignancy35
Chondromyxoid fibroma12
Non-tumorous59
Sclerotic lesions24
Ameloblastic fibroma12
Odontogenic myxoma12
Total57100
Table 2 Comparison of morphological characteristics between ameloblastoma and non-ameloblastoma groups
Variable
Ameloblastoma (n = 20)
Non-ameloblastoma (n = 37)
P value
Volume, cm373.6 (7.6–1014)39.12 (0.6–1296)< 0.05
Cystic/necrotic areas10051< 0.05
Cortical expansion/thinning10078< 0.05
Mandibular canal involvement6032< 0.05
Retromolar trigone involvement4518< 0.05
Table 3 Classification of lesions based on iodine concentration (μg/mL)
Iodine concentration (μg/mL)
0-15 (low)
16-30 (moderate)
31-45 (high)
≥ 46 (extreme)
Ameloblastoma21141
CGCG0180
OKC5000
OF0300
Salivary gland tumor1100
Chondromyxoid fibroma0001
Others4621
Table 4 Comparison of dual-energy computed tomography quantitative parameters between subgroups
Parameters
Amelo, mean ± SD
OKC, mean ± SD
CGCG, mean ± SD
Other JT, mean ± SD
1P value
2P value
3P value
Mean HU122 ± 28.333 ± 12.4151 ± 24.3117 ± 37.90.007< 0.0010.616
IC29 ± 9.37.2 ± 5.836.1 ± 6.824.8 ± 11.50.036< 0.0010.232
WC1032.5 ± 131010 ± 111043 ± 11.61040 ± 11.40.0360.0440.056
NIC0.35 ± 0.150.10 ± 0.10.59 ± 0.250.39 ± 0.240.0110.0070.501
WC (cystic)997 ± 5.61020 ± 5---< 0.001-
Table 5 Receiver operating characteristic analysis of dual-energy computed tomography parameters between ameloblastoma and central giant cell granulomas
Variable
Cutoff value
Sensitivity, %
Specificity, %
AUC
SE
IC32.181.8265.000.7270.0955
Mean HU13481.8265.000.7890.0832
WC103672.7350.000.66590.1
NIC0.481.8270.000.7950.0970
Table 6 Comparison of dual-energy computed tomography quantitative parameters based on morphology
Lytic unilocular (n = 21)Amelo, n = 7 (mean ± SD)OKC, n = 6 (mean ± SD)CGCG, n = 2 (mean ± SD)OF, n = 2 (mean ± SD)Non-tumorous, n = 4 (mean ± SD)
Mean HU115 ± 18.333 ± 12.4135 ± 2487 ± 17.967 ± 17.9
IC28 ± 8.37.2 ± 5.832.9 ± 6.818.8 ± 9.58.8 ± 9.5
WC1030.5 ± 12.81010 ± 11.31043 ± 11.61038 ± 11.41018 ± 11.4
NIC0.37 ± 0.150.10 ± 0.10.72 ± 0.30.45 ± 0.240.25 ± 0.24
Lytic multilocular (n = 18)Amelo, n = 8 (mean ± SD)CGCG, n = 4 (mean ± SD)SG tumors, n = 2 (mean ± SD)Malignancy, n = 3 (mean ± SD)Non-tumorous, n = 1 (mean ± SD)
Mean HU123 ± 21.3152 ± 20.494.2 ± 24.3120 ± 37.969 ± 18.9
IC29 ± 9.335.1 ± 9.817.85 ± 6.824.8 ± 11.510 ± 2.5
WC1032.5 ± 12.81048 ± 11.31038 ± 11.61040 ± 11.41011 ± 11.4
NIC0.35 ± 0.150.54 ± 0.190.18 ± 0.050.39 ± 0.240.29 ± 0.1
Mixed-sclerotic (n = 16)Amelo, n = 5 (mean ± SD)CGCG, n = 5 (mean ± SD)OFs, n = 4 (mean ± SD)CMF, n = 1 (mean ± SD)Non-tumorous, n = 1 (mean ± SD)
Mean HU129 ± 20.3158 ± 20.4143.8 ± 24.3164 ± 37.977 ± 16
IC29.5 ± 9.338.2 ± 9.831.1 ± 6.849.8 ± 11.511.8 ± 9
WC1032.5 ± 12.81048 ± 11.31043 ± 11.61037 ± 11.41028 ± 20.4
NIC0.35 ± 0.150.60 ± 0.190.66 ± 0.250.37 ± 0.240.19 ± 0.14